iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
77 hedge funds and large institutions have $841M invested in iTeos Therapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 18 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% more capital invested
Capital invested by funds: $754M → $841M (+$87.7M)
4.52% more ownership
Funds ownership: 83.95% → 88.47% (+4.5%)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
7% less funds holding
Funds holding: 83 → 77 (-6)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$25.8M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$17.8M |
| 3 |
RI
RTW Investments
New York
|
+$16.6M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.99M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$6.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$27.1M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$9.81M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$6.05M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$4.68M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$2.26M |
ITOS Hedge Fund Activity: Q3 2021 in Review
77 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2021, worth a combined $841M — up 12% from $754M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ITOS and 12 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 27 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $25.8M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $27.1M sold.
- 77 institutional investors held iTeos Therapeutics (ITOS) as of Q3 2021, down from 83 in Q2 2021.
- Funds reported $841M of iTeos Therapeutics stock for Q3 2021, up 12% quarter-over-quarter.
- 12 funds opened new iTeos Therapeutics positions in Q3 2021 and 18 closed out, a net change of -6 holders.
- The largest iTeos Therapeutics buyer in Q3 2021 was Rubric Capital Management (New York), an estimated $25.8M added.
- The largest iTeos Therapeutics seller in Q3 2021 was Janus Henderson Group, an estimated $27.1M sold.
Based on aggregated 13F filings for Q3 2021.